PHIBRO ANIMAL HEALTH CORP
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
PAHC$34.64+0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows
| | | | | | | | |
|---|---|---|---|---|---|---|---|
| · · Three Months · | |||||||
| For the Periods Ended September 30 · 2025 · 2024 · | |||||||
| · · (unaudited) · | |||||||
| · · (in thousands) · | |||||||
| OPERATING ACTIVITIES · · · | |||||||
| Net income | | $26,527 | | $6,975 | | ||
| Adjustments to reconcile net income to | | | | | | ||
| net cash provided by operating activities: | | | | | | ||
| Depreciation and amortization | | 12,830 | | 9,004 | | ||
| Amortization of debt issuance costs | | 572 | | 367 | | ||
| Deferred income taxes | | 2,171 | | (4,883) | | ||
| Foreign currency gains, net | | (239) | | (517) | | ||
| Acquisition-related items | | | 1,117 | | | — | |
| Stock-based compensation expense | | | 339 | | | 179 | |
| Other | | (474) | | (461) | | ||
| Changes in operating assets and liabilities, net of business acquisition | | | | | | ||
| Accounts receivable, net | | 11,366 | | 9,208 | | ||
| Inventories, net | | (26,181) | | (5,164) | | ||
| Other current assets | | (306) | | (979) | | ||
| Other assets | | (105) | | 1,113 | | ||
| Accounts payable | | (4,627) | | 1,304 | | ||
| Accrued expenses and other liabilities | | (13,688) | | (3,524) | | ||
| Net cash provided by operating activities | | 9,302 | | 12,622 | | ||
| INVESTING ACTIVITIES | | | | ||||
| Purchases of short-term investments | | (12,504) | | — | | ||
| Maturities of short-term investments | | 9,000 | 6,000 | | |||
| Capital expenditures | | | (13,806) | (9,583) | | ||
| Other, net | | (3,704) | | 653 | | ||
| Net cash used by investing activities | | (21,014) | | (2,930) | | ||
| FINANCING ACTIVITIES | | | | | | ||
| Revolving credit facility borrowings | | 86,000 | | 267,000 | | ||
| Revolving credit facility repayments | | (58,000) | | (264,000) | | ||
| Proceeds from long-term debt | | | — | | | 300,000 | |
| Payments of long-term debt | | (4,063) | | (315,015) | | ||
| Debt issuance costs | | | — | | | (10,377) | |
| Payments of insurance premium financing and other short-term debt | | | (2,738) | | | (1,945) | |
| Dividends paid | | (4,864) | | (4,860) | | ||
| Net cash provided (used) by financing activities | | 16,335 | | (29,197) | | ||
| Effect of exchange rate changes on cash | | 107 | | 729 | | ||
| Net increase (decrease) in cash and cash equivalents | | 4,730 | | (18,776) | | ||
| Cash and cash equivalents at beginning of period | | 68,039 | | 70,613 | | ||
| Cash and cash equivalents at end of period | | $72,769 | | $51,837 | | ||
PHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIES
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.